This product uses the truncated VZV gE protein with independent intellectual property rights of our company as the antigen, and contains major B-cell and T-cell epitopes. Equipped with the self-developed dual adjuvant system, it can induce the body to produce strong specific humoral and cellular immune responses. All adjuvants used have been applied in marketed vaccines.
This product obtained China's IND approval in August 2024. It initiated Phase I clinical research in February 2025, and has completed phased safety observation, showing good safety. In July 2025, it entered the Phase II clinical research stage.

For all the above-mentioned products, we are seeking localized cooperation, technology transfer, and agency partnerships in overseas markets.